
In the phase 4 STAR trial, guselkumab improved BASDAI and MRI sacroiliac joint inflammation vs placebo at week 24 in axial psoriatic arthritis.

In the phase 4 STAR trial, guselkumab improved BASDAI and MRI sacroiliac joint inflammation vs placebo at week 24 in axial psoriatic arthritis.

Twelve-month REDUCE-2 data on deeper serum urate targets, renal adverse events and the flare and tophi readouts still to come.

REDUCE-2 investigator Puja Khanna on gaps in oral urate-lowering therapy and why a selective URAT1 inhibitor was tested.

Maxime Samson, MD, PhD, discusses phase 2b data showing ustekinumab plus prednisone tripled sustained remission vs prednisone alone in relapsing GCA.

Pooled UPHOLD and CLOSE-UP data from 2111 patients show 63.1% remained on upadacitinib at 24 months, with no new safety signals.

Matthew Baker, MD, MS, discusses INDIGO data showing obexelimab lowered cumulative glucocorticoid toxicity in IgG4-related disease at ACR 2026.

A FIBRONEER-ILD subgroup analysis presented at ACR 2026 found no heterogeneity in nerandomilast's effect on FVC decline or clinical events.

Phase 1 Breakfree-1 data show sustained SLE activity reductions and 91% off immunosuppressants at month 12 after zola-cel.

Ghaith Noaiseh, MD, explains how dazodalibep’s CD40 ligand blockade works and reviews dryness and safety data from OASIZ-301 at ACR 2026.

Ghaith Noaiseh, MD, discusses phase 3 OASIZ-301 results showing dazodalibep reduced systemic disease activity in Sjögren’s disease at ACR 2026.

John Stone, MD, MPH, discusses INDIGO open-label extension data showing durable flare control with obexelimab in IgG4-related disease at ACR 2026.

Afimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.

ACR 2026 real-world data associate upadacitinib with greater joint count reductions than IL-17 inhibitors after prior TNF inhibitor use.

PERIS interim data show improvements in joint, entheseal, and skin outcomes with risankizumab in patients with PsA.

ACR 2026 data link circulating protein signatures to PsA disease activity and treatment response with deucravacitinib.

Furie explains how nipocalimab clears IgG autoantibodies and why the JASMINE subgroups could shape phase 3.

The 200-mg dose improved ACR20 response vs placebo at week 16 in biologic-naïve patients, while the 400-mg dose added no benefit.

An international IgG4ward! Foundation panel issued 28 treatment statements for IgG4-related diseases, with consensus reached on 22.

In 33 patients with myositis-associated ILD from FIBRONEER-ILD, nerandomilast numerically slowed FVC decline and lowered progression risk.

RESET-RA 24-month data show sustained clinical responses with vagus nerve stimulation in patients with treatment-experienced RA.

In a matched claims analysis, 94% of patients with PMR initiating sarilumab discontinued glucocorticoids by 12 months vs 78% initiating methotrexate.

Patients with relapsing GCA who stopped upadacitinib after year 1 flared sooner and needed far more glucocorticoids than new-onset patients.

In year 2 of SELECT-GCA, 6.0% of patients continuing upadacitinib flared vs 55.9% switched to placebo.

Philip Mease, MD, discusses BE BOLD head-to-head results plus new indirect and real-world comparisons shaping PsA treatment choices at ACR 2026.

Phase 3 data presented at ACR Convergence 2026 show up to 28.7% weight loss with the triple agonist, alongside sustained knee pain relief.

In phase 1 COMPARE, 4 of 6 patients with refractory RA achieved remission by week 36 following CD19 CAR T-cell therapy.

ACR 2026 data show 56.7% of patients with PsA met GLP-1 RA eligibility criteria, but only 15.7% were prescribed treatment.

SABLE registry data show numerically lower 5-year mortality with belimumab vs conventional immunosuppressants in patients with SLE.

Once-weekly retatrutide reduced WOMAC pain and body weight vs placebo in two phase 3 trials, with up to 69.6% of participants halving knee pain at week 68.

Philip Mease, MD, discusses TOGETHER-PsA data on ixekizumab plus tirzepatide and why addressing obesity is becoming central to PsA care.